Versanis Bio scores $70m Series A
Versanis Bio, a developer of medicines that address medical conditions prevalent in older adults, has secured $70 million in Series A financing.
Versanis Bio, a developer of medicines that address medical conditions prevalent in older adults, has secured $70 million in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination